We are live on
!
Find out more
LGM
Logos Global Management Portfolio holdings
AUM
$1.94B
1-Year Est. Return
444.09%
This Fund
S&P 500
This Quarter
Est. Return
+88.59%
1 Year Est. Return
+444.09%
3 Year Est. Return
+1,593.63%
5 Year Est. Return
+2,146.66%
10 Year Est. Return
–
AUM
$1.5B
AUM Growth
+$488M
(+48%)
Cap. Flow
+$86.9M
Cap. Flow
% of AUM
5.79%
Top 10 Holdings %
Top 10 Hldgs %
50.22%
Holding
80
New
22
Increased
15
Reduced
20
Closed
11
Top Buys
| 1 |
Praxis Precision Medicines
PRAX
|
+$46.6M |
| 2 |
Tango Therapeutics
TNGX
|
+$28M |
| 3 |
IDEAYA Biosciences
IDYA
|
+$27.9M |
| 4 |
Immunovant
IMVT
|
+$24.5M |
| 5 |
MoonLake Immunotherapeutics
MLTX
|
+$20.6M |
Top Sells
| 1 |
AKRO
Akero Therapeutics
AKRO
|
+$57M |
| 2 |
Arvinas
ARVN
|
+$47.5M |
| 3 |
Dyne Therapeutics
DYN
|
+$21.8M |
| 4 |
Verastem
VSTM
|
+$20.9M |
| 5 |
Protagonist Therapeutics
PTGX
|
+$19.9M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Revolution Medicines
RVMD
$39.2B
| $159M | 10.62% |
2,000,000
+250,000
| +14% | +$16.4M |
|
|
2
Praxis Precision Medicines
PRAX
$8.88B
| $111M | 7.37% |
375,000
+250,000
| +200% | +$46.6M |
|
|
3
IDEAYA Biosciences
IDYA
$3.54B
| $108M | 7.2% |
3,125,000
+875,000
| +39% | +$27.9M |
|
4
Olema Pharmaceuticals
OLMA
$1.03B
| $80.2M | 5.35% |
3,208,875
| – | – |
|
|
5
CALL
Revolution Medicines
RVMD
$39.2B
| $79.7M | 5.31% |
1,000,000
| – | – |
|
|
CDTX
6
DELISTED
Cidara Therapeutics
CDTX
| $68.5M | 4.56% |
310,000
-65,000
| -17% | -$10.5M |
|
|
ABVX
7
Abivax
ABVX
$11.9B
| $53.9M | 3.59% |
400,000
-15,000
| -4% | -$1.64M |
|
8
Erasca
ERAS
$6.61B
| $48.4M | 3.22% |
13,000,000
-2,150,000
| -14% | -$6.05M |
|
9
Ocular Therapeutix
OCUL
$2.18B
| $42.5M | 2.83% |
3,500,000
+250,000
| +8% | +$3.04M |
|
10
Structure Therapeutics
GPCR
$3.53B
| $41.7M | 2.78% |
600,000
-250,000
| -29% | -$10.2M |
|
11
Disc Medicine
IRON
$2.9B
| $40.5M | 2.7% |
510,000
+60,000
| +13% | +$5.07M |
|
|
MAZE
12
Maze Therapeutics
MAZE
$1.63B
| $39.4M | 2.62% |
950,000
-277,300
| -23% | -$9.53M |
|
|
13
Tango Therapeutics
TNGX
$4.93B
| $37.2M | 2.48% |
4,200,000
+3,250,000
| +342% | +$28M |
|
|
RNAM
14
DELISTED
Avidity Biosciences
RNAM
| $36.1M | 2.4% |
500,000
-100,000
| -17% | -$6.46M |
|
15
Biogen
BIIB
$29.1B
| $35.2M | 2.35% |
200,000
+100,000
| +100% | +$16.3M |
|
|
16
Immunovant
IMVT
$8.19B
| $35M | 2.33% |
1,375,000
+1,100,000
| +400% | +$24.5M |
|
17
Jazz Pharmaceuticals
JAZZ
$15B
| $34M | 2.27% |
200,000
| – | – |
|
|
TERN
18
DELISTED
Terns Pharmaceuticals
TERN
| $30.3M | 2.02% |
+750,000
| New | +$17.3M |
|
19
Vaxcyte
PCVX
$8.19B
| $30M | 2% |
650,000
+25,000
| +4% | +$1.12M |
|
20
Immunocore
IMCR
$1.76B
| $29.5M | 1.97% |
850,000
| – | – |
|
|
LBRX
21
LB Pharmaceuticals
LBRX
$922M
| $26.7M | 1.78% |
1,200,000
+70,000
| +6% | +$1.22M |
|
|
APLS
22
CALL
DELISTED
Apellis Pharmaceuticals
APLS
| $25.1M | 1.67% |
1,000,000
| – | – |
|
23
CALL
Arcus Biosciences
RCUS
$3.52B
| $25M | 1.67% |
+1,050,000
| New | +$21.4M |
|
|
24
Dyne Therapeutics
DYN
$3.97B
| $24.4M | 1.63% |
1,250,000
-1,150,000
| -48% | -$21.8M |
|
25
Design Therapeutics
DSGN
$844M
| $23.4M | 1.56% |
2,500,000
-1,155,000
| -32% | -$9.04M |
|
Similar funds
NFG
FFH
BC
MWA
WPC
OCM
1SB
FM